Abstract
A case is described of a patient who developed local cutaneous hypersensitivity soon after commencing treatment with monocomponent insulins (MCI). This appears to be the first record of such a case.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have